MarginsXMarginsX
Home › Markets › Health Care › BGLC

BioNexus Gene Lab Corp (BGLC)

BGLC trades on Nasdaq in Health Care, Medical Specialities. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$0.8200
-0.12% on the day
Market cap
$2.4M
Nano cap
Revenue · 2025
$7.4M
-21.9% on 2024
Net income · 2025
-$3.0M
-40.2% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1737523/000147793226002218/0001477932-26-002218-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerBGLC on Nasdaq
SectorHealth Care
IndustryMedical Specialities
CountryMalaysia
IPO yearNot reported by the screener
SEC CIK0001737523
SEC industry codeServices-Medical Laboratories
Incorporated inWY

Financials · 2025

LineValue
Revenue$7.4M
Net income-$3.0M
Operating income-$3.0M
Net margin-40.2%
Operating margin-39.9%
Revenue growth-21.9%
Cash$2.5M
Total assets$9.3M
P/E (computed)Net income was not positive
P/S (computed)0.3×

Warning signs

Cash runway
17.5 months
$1.2M cash at June 30, 2026
Share count, 1 year
+63.3%
2025-08-18 to 2026-08-14 · +65.7% over 3 years
Going-concern doubt
Yes
10-Q filed August 14, 2026
Insider net buying, 12 months
$0
Through September 30, 2026
SignFindingSource
Going concernStates substantial doubt about continuing as a going concern.
"These factors raise substantial doubt about the Company's ability to continue as a going concern within one year of the date that the financial statements are issued."
10-Q 2026-08-14
Cash and burn$1.2M cash; operating cash flow -$212K a quarter.Report 2026-06-30
Shares outstanding2,933,442 (2026-08-14); 1,796,597 a year earlier; 17,698,549 three years earlier. 3y figure adjusted for split (1-for-10 overall).Cover page 2026-08-14
Reverse splits, 3 years1; latest 1-for-10 on 2025-04-07Source 2025-04-07
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorJP CENTURION & PARTNERS PLT, Kuala Lumpur, MalaysiaPCAOB Form AP 2026-04-23
Late filings, 12 months1 NT noticeNT 10-K 2026-03-31
Insider trades, 12 monthsBought $0, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q2 2026
2026-06-30
$76K-$286K-$422K$1.2MNo debt tags$3.1M10-Q 2026-08-14
Q1 2026
2026-03-31
$23K-$544K-$148K$1.3MNo debt tags$5.3M10-Q 2026-05-15
Q4 2025
2025-12-31
$484K-$1.0M$961K$2.4MNo debt tags$7.4M10-K 2026-04-14
Q3 2025
2025-09-30
$2.5M-$709K-$1.2M$1.2MNo debt tags$9.5M10-Q 2025-11-14
Q2 2025
2025-06-30
$2.3M-$616K-$738K$1.5MNo debt tags$9.6M10-Q 2026-08-14
Q1 2025
2025-03-31
$2.1M-$623K-$824K$2.1MNo debt tags$9.3M10-Q 2026-05-15
Q4 2024
2024-12-31
$2.5M-$348K$219K$2.9MNo debt tags$9.5M10-K 2026-04-14
Q3 2024
2024-09-30
$2.6M-$1.3M-$1.6M$4.1MNo debt tags$9.3M10-Q 2025-11-14

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document
FORM S-3
S-32025-11-07
Latest annual report
FORM 10-K
10-K2026-04-14
Latest quarterly / interim
FORM 10-Q
10-Q2026-08-14
Latest current report
FORM 8-K
8-K2026-10-07
Latest proxyDEF 14A2025-12-03

Source: SEC EDGAR submissions feed, 158 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-1.1%
1 month-37.8%
3 months-49.9%
Year to date-79.2%
1 year-81.8%
From 52-week high-82.9%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Medical Specialities

TickerCompanyPriceDayMarket cap
ADVBAdvanced Biomed Inc.$2.22-12.25%$3.7M
ACONAclarion Inc.$1.39-12.58%$4.0M
ACHAccendra Health Inc.$0.0857-35.08%$6.6M
AMSAmerican Shared Hospital Services$1.07-0.93%$7.1M
MDXHMDxHealth SA$0.1490+3.40%$14.2M
SERASera Prognostics Inc.$1.94-3.48%$77.2M
XGNExagen Inc.$3.77-8.72%$96.2M
BDSXBiodesix Inc.$9.00-8.91%$99.8M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier